736
Views
159
CrossRef citations to date
0
Altmetric
Review

Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment

, &
Pages 549-560 | Published online: 10 Mar 2015

References

  • WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
  • StrachanMWReynoldsRMMarioniREPriceJFCognitive function, dementia and type 2 diabetes mellitus in the elderlyNat Rev Endocrinol20117210811421263438
  • BiesselsGJStaekenborgSBrunnerEBrayneCScheltensPRisk of dementia in diabetes mellitus: a systematic reviewLancet Neurol200651647416361024
  • CukiermanTGersteinHWilliamsonJCognitive decline and dementia in diabetes – systematic overview of prospective observational studiesDiabetologia200548122460246916283246
  • StrachanMWDearyIJEwingFMFrierBMIs type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studiesDiabetes Care19972034384459051402
  • PrinceMBryceRAlbaneseEWimoARibeiroWFerriCPThe global prevalence of dementia: a systematic review and meta-analysisAlzheimers Dement201391637523305823
  • StrachanMWPriceJFFrierBMDiabetes, cognitive impairment, and dementiaBMJ20083367634618174567
  • Alzheimer’s Association2014 Alzheimer’s disease facts and figuresAlzheimers Dement2014102e47e9224818261
  • BeydounMALhotskyAWangYAssociation of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer’s diseaseAm J Epidemiol2008168101179118918835864
  • PeilaRRodriguezBLWhiteLRLaunerLJFasting insulin and incident dementia in an elderly population of Japanese–American menNeurology200463222823315277613
  • SjoholmANystromTInflammation and the etiology of type 2 diabetesDiabetes Metab Res Rev200622141015991254
  • LuchsingerJAType 2 diabetes and cognitive impairment: linking mechanismsJ Alzheimer’s Dis201230Suppl 2S185S19822433668
  • de la MonteSMContributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s diseaseDrugs2012721496622191795
  • LanctotKLRajaramRDHerrmannNTherapy for Alzheimer’s disease: how effective are current treatments?Ther Adv Neurol Disord20092316318021179526
  • GreenRCSchneiderLSAmatoDAEffect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trialJAMA2009302232557256420009055
  • QuinnJFRamanRThomasRGDocosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJAMA2010304171903191121045096
  • QuerfurthHWLaFerlaFMAlzheimer’s diseaseN Engl J Med2010362432934420107219
  • SelkoeDJAlzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-proteinJ Alzheimers Dis200131758012214075
  • MoreiraPISantosMSSeicaROliveiraCRBrain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetesJ Neurol Sci20072571–220621417316694
  • MoreiraPIHondaKZhuXBrain and brawn: parallels in oxidative strengthNeurology2006662 Suppl 1S97S10116432155
  • GoedertMSpillantiniMGA century of Alzheimer’s diseaseScience2006314580077778117082447
  • HardyJAllsopDAmyloid deposition as the central event in the aetiology of Alzheimer’s diseaseTrends Pharmacol Sci199112103833881763432
  • HardyJSelkoeDJThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience2002297558035335612130773
  • HardyJAHigginsGAAlzheimer’s disease: the amyloid cascade hypothesisScience199225650541841851566067
  • RocchiAPellegriniSSicilianoGMurriLCausative and susceptibility genes for Alzheimer’s disease: a reviewBrain Res Bull200361112412788204
  • CummingsJLAlzheimer’s diseaseN Engl J Med20043511566715229308
  • SmithADYaffeKDementia (including Alzheimer’s disease) can be prevented: statement supported by international expertsJ Alzheimers Disease201438469970324326609
  • DeFronzoRALilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDMDiabetes19883766676873289989
  • StefanNKantartzisKMachannJIdentification and characterization of metabolically benign obesity in humansArch Intern Med2008168151609161618695074
  • LuchsingerJAGustafsonDRAdiposity, type 2 diabetes, and Alzheimer’s diseaseJ Alzheimers Disease200916469370419387106
  • OttAStolkRPvan HarskampFPolsHAHofmanABretelerMMDiabetes mellitus and the risk of dementia: the Rotterdam StudyNeurology19995391937194210599761
  • LuchsingerJReitzCHonigLSTangM-XSheaSMayeuxRAggregation of vascular risk factors and risk of incident Alzheimer diseaseNeurology200565454555116116114
  • GudalaKBansalDSchifanoFBhansaliADiabetes mellitus and risk of dementia: a meta-analysis of prospective observational studiesJ Diabetes Investig201346640650
  • ChengGHuangCDengHWangHDiabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studiesIntern Med J201242548449122372522
  • CurbJDRodriguezBLAbbottRDLongitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose toleranceNeurology199952597197510102414
  • WhitmerRASidneySSelbyJJohnstonSCYaffeKMidlife cardiovascular risk factors and risk of dementia in late lifeNeurology200564227728115668425
  • Schnaider BeeriMGoldbourtUSilvermanJMDiabetes mellitus in midlife and the risk of dementia three decades laterNeurology200463101902190715557509
  • PeilaRRodriguezBLLaunerLJType 2 diabetes, APOE gene, and the risk for dementia and related pathologies The Honolulu-Asia Aging StudyDiabetes20025141256126211916953
  • TakedaMMartinezRKudoTApolipoprotein E and central nervous system disorders: reviews of clinical findingsPsychiatry Clin Neurosci201064659260721105952
  • IrieFFitzpatrickALLopezOLEnhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition StudyArch Neurol2008651899318195144
  • DoreGAEliasMFRobbinsMAEliasPKNagyZPresence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse StudyDiabetologia200952122551256019693485
  • YaffeKBlackwellTWhitmerRAKruegerKBarrett ConnorEGlycosylated hemoglobin level and development of mild cognitive impairment or dementia in older womenJ Nutr Health Aging200610429329516886099
  • XuWLQiuCXWahlinAWinbladBFratiglioniLDiabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up studyNeurology20046371181118615477535
  • ProfennoLAPorsteinssonAPFaraoneSVMeta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disordersBiol Psychiatry201067650551219358976
  • ReavenGMLawsAInsulin Resistance: The Metabolic Syndrome XClifton, NJ, USAHuman Press1999
  • AnsteyKCherbuinNBudgeMYoungJBody mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studiesObes Rev2011125e426e43721348917
  • GustafsonDRothenbergEBlennowKSteenBSkoogIAn 18-year follow-up of overweight and risk of Alzheimer diseaseArch Intern Med2003163131524152812860573
  • FitzpatrickALKullerLHLopezOLMidlife and late-life obesity and the risk of dementia: cardiovascular health studyArch Neurol200966333634219273752
  • WhitmerRAThe epidemiology of adiposity and dementiaCurr Alzheimer Res20074211712217430233
  • MorleyJEAnorexia, sarcopenia, and agingNutrition200117766066311448592
  • JohnsonDKWilkinsCHMorrisJCAccelerated weight loss may precede diagnosis in Alzheimer diseaseArch Neurol20066391312131716966511
  • LuchsingerJATangM-XSheaSMayeuxRHyperinsulinemia and risk of Alzheimer diseaseNeurology20046371187119215477536
  • OkerekeOHankinsonSEHuFBGrodsteinFPlasma C peptide level and cognitive function among older women without diabetes mellitusArch Intern Med2005165141651165616043685
  • OkerekeOIPollakMNHuFBHankinsonSESelkoeDJGrodsteinFPlasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetesPsychoneuroendocrinology200833445546118261857
  • OkerekeOIKurthTPollakMNGazianoJMGrodsteinFFasting plasma insulin, c-peptide and cognitive change in older men without diabetes: results from the Physicians’ Health Study IINeuroepidemiology201034420020720197703
  • AvogaroPCrepaldiGEnziGTiengoAAssociation of hyperlipemia, diabetes mellitus and mild obesityActa Diabetol Lat19674572590
  • YaffeKKanayaALindquistKThe metabolic syndrome, inflammation, and risk of cognitive declineJAMA2004292182237224215536110
  • VanhanenMKoivistoKMoilanenLAssociation of metabolic syndrome with Alzheimer disease. A population-based studyNeurology200667584384716966548
  • KalmijnSFoleyDWhiteLMetabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia Aging StudyArterioscler Thromb Vasc Biol200020102255226011031212
  • RaffaitinCGinHEmpanaJ-PMetabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City StudyDiabetes Care200932116917418945929
  • SolfrizziVScafatoECapursoCMetabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on AgeingJ Neurol Neurosurg Psychiatry201081443344019965842
  • MullerMTangM-XSchupfNManlyJJMayeuxRLuchsingerJAMetabolic syndrome and dementia risk in a multiethnic elderly cohortDement Geriatr Cogn Disord200724318519217641531
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA2001285192486249711368702
  • GrundySMCleemanJIDanielsSRDiagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statementCirculation2005112172735275216157765
  • AlbertiKGZimmetPShawJIDF Epidemiology Task Force Consensus GroupThe metabolic syndrome – a new worldwide definitionLancet200536694911059106216182882
  • CrichtonGEEliasMFBuckleyJDMurphyKJBryanJFrisardiVMetabolic syndrome, cognitive performance, and dementiaJ Alzheimers Dis201230S77S8721971405
  • WattsASLoskutovaNBurnsJMJohnsonDKMetabolic syndrome and cognitive decline in early Alzheimer’s disease and healthy older adultsJ Alzheimers Dis201335225326523388170
  • ZhaoW-QDe FeliceFGFernandezSAmyloid beta oligomers induce impairment of neuronal insulin receptorsFASEB J200822124626017720802
  • MoloneyAMGriffinRJTimmonsSO’ConnorRRavidRO’NeillCDefects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signallingNeurobiol Aging201031222424318479783
  • SteenETerryBMRiveraEJImpaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes?J Alzheimers Dis200571638015750215
  • HoyerSNitschRCerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer typeJ Neural Transm19897532272322926384
  • CraftSAlzheimer disease: insulin resistance and AD – extending the translational pathNat Rev Neurol20128736036222710630
  • TalbotKWangH-YKaziHDemonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive declineJ Clin Invest201212241316133822476197
  • HirosumiJTuncmanGChangLA central role for JNK in obesity and insulin resistanceNature2002420691333333612447443
  • BomfimTRForny-GermanoLSathlerLBAn anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomersJ Clin Invest201212241339135322476196
  • RiveraEJGoldinAFulmerNTavaresRWandsJRde la MonteSMInsulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholineJ Alzheimers Dis20058324726816340083
  • PhielCJWilsonCALeeVM-YKleinPSGSK-3α regulates production of Alzheimer’s disease amyloid-β peptidesNature2003423693843543912761548
  • WadaAYokooHYanagitaTKobayashiHNew twist on neuronal insulin receptor signaling in health, disease, and therapeuticsJ Pharmacol Sci200599212814316210778
  • CarroETrejoJLSpuchCBohlDHeardJMTorres-AlemanIBlockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer’s-like neuropathology in rodents: new cues into the human disease?Neurobiol Aging200627111618163116274856
  • CarroETorres-AlemanIThe role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s diseaseEur J Pharmacol2004490112713315094079
  • BakerLDCrossDJMinoshimaSBelongiaDWatsonGSCraftSInsulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetesArch Neurol2011681515720837822
  • DeviLAlldredMJGinsbergSDOhnoMMechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s diseasePLoS One201273e3279222403710
  • PlumLSchubertMBrüningJCThe role of insulin receptor signaling in the brainTrends Endocrinol Metab2005162596515734146
  • GaspariniLNetzerWJGreengardPXuHDoes insulin dysfunction play a role in Alzheimer’s disease?Trends Pharmacol Sci200223628829312084635
  • KremerALouisJVJaworskiTVan LeuvenFGSK3 and Alzheimer’s disease: facts and fictionFront Mol Neurosci201141721904524
  • LiXLuFTianQYangYWangQWangJZActivation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in cultureJ Neural Transm200611319310215959856
  • PiconePGiacomazzaDVetriVInsulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular traffickingAging Cell201110583284321624038
  • SuzanneMContributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s diseaseDrugs2012721496622191795
  • ThorneRPronkGPadmanabhanVFreyWH2ndDelivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administrationNeuroscience2004127248149615262337
  • RegerMWatsonGGreenPIntranasal insulin improves cognition and modulates β-amyloid in early ADNeurology200870644044817942819
  • CraftSBakerLDMontineTJIntranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trialArch Neurol2012691293821911655
  • RegerMWatsonGFreyWH2ndEffects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotypeNeurobiol Aging200627345145815964100
  • KitabchiAETemprosaMKnowlerWCDiabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metforminDiabetes20055482404241416046308
  • GoldbergRHortonEMarcovinaSIntensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceDiabetes20055451566157215855347
  • OrchardTJTemprosaMGoldbergRThe effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trialAnn Intern Med2005142861161915838067
  • KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
  • EvansJMDonnellyLAEmslie-SmithAMAlessiDRMorrisADMetformin and reduced risk of cancer in diabetic patientsBMJ200533075031304130515849206
  • CurrieCPooleCGaleEThe influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia20095291766177719572116
  • DomínguezROMarschoffERGonzálezSERepettoMGSerraJAType 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer’s disease patientsDiabetes Res Clin Pract2012981687422658669
  • HsuC-CWahlqvistMLLeeM-STsaiH-NIncidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metforminJ Alzheimers Dis201124348549321297276
  • ImfeldPBodmerMJickSSMeierCRMetformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control studyJ Am Geriatr Soc201260591692122458300
  • Yki-JärvinenHThiazolidinedionesN Engl J Med2004351111106111815356308
  • MalinowskiJMBolestaSRosiglitazone in the treatment of type 2 diabetes mellitus: a critical reviewClin Ther200022101151116811110228
  • NestoRC-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinedionesDiabet Med200421881081715270782
  • TuppoEEAriasHRThe role of inflammation in Alzheimer’s diseaseInt J Biochem Cell Biol200537228930515474976
  • CraftSInsulin resistance and Alzheimers disease pathogenesis: potential mechanisms and implications for treatmentCurr Alzheimer Res20074214715217430239
  • WatsonGCholertonBARegerMAPreserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary studyAm J Geriatr Psychiatry2005131195095816286438
  • RisnerMSaundersAAltmanJEfficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s diseasePharmacogenomics J20066424625416446752
  • GoldMAldertonCZvartau-HindMRosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III studyDement Geriatr Cogn Disord201030213114620733306
  • MillerBWWillettKCDesiletsARRosiglitazone and pioglitazone for the treatment of Alzheimer’s diseaseAnn Pharmacother201145111416142422028424
  • CheungBMBehind the rosiglitazone controversyExpert Rev Clin Pharmacol20103672372522111775
  • DeaconCFAhrénBPhysiology of incretins in health and diseaseRev Diabet Stud20118329322262068
  • DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
  • DeaconCDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes Obes Metab201113171821114598
  • LovshinJADruckerDJIncretin-based therapies for type 2 diabetes mellitusNat Rev Endocrinol20095526226919444259
  • VilsbøllTKrarupTMadsbadSHolstJJBoth GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjectsRegul Pept2003114211512112832099
  • DuringMJCaoLZuzgaDSGlucagon-like peptide-1 receptor is involved in learning and neuroprotectionNat Med2003991173117912925848
  • AbbasTFaivreEHölscherCImpairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer’s diseaseBehav Brain Res2009205126527119573562
  • McCleanPLParthsarathyVFaivreEHölscherCThe diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s diseaseJ Neurosci201131176587659421525299
  • SelkoeDJPreventing Alzheimer’s diseaseScience201233761011488149222997326
  • PipatpiboonNPintanaHPratchayasakulWChattipakornNChattipakornSCDPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumptionEur J Neurosci201337583984923240760
  • PintanaHApaijaiNChattipakornNChattipakornSCDPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant ratsJ Endocrinol2013218111123591914
  • TyasSLManfredaJStrainLAMontgomeryPRRisk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, CanadaInt J Epidemiol200130359059711416089
  • MacKnightCRockwoodKAwaltEMcDowellIDiabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and AgingDement Geriatr Cogn Disord2002142778312145454
  • HassingLBJohanssonBNilssonSEDiabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest oldInt Psychogeriatr200214323924812475085
  • HonigLSTangMXAlbertSStroke and the risk of Alzheimer diseaseArch Neurol200360121707171214676044
  • ArvanitakisZWilsonRSBieniasJLEvansDABennettDADiabetes mellitus and risk of Alzheimer disease and decline in cognitive functionArch Neurol200461566166615148141
  • BorensteinARWuYMortimerJADevelopmental and vascular risk factors for Alzheimer’s diseaseNeurobiol Aging200526332533415639310
  • HaydenKMZandiPPLyketsosCGVascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County studyAlzheimer Dis Assoc Disord20062029310016772744
  • AkomolafeABeiserAMeigsJBDiabetes mellitus and risk of developing Alzheimer disease: results from the Framingham StudyArch Neurol200663111551155517101823
  • AhtiluotoSPolvikoskiTPeltonenMDiabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic studyNeurology201075131195120220739645
  • OharaTDoiYNinomiyaTGlucose tolerance status and risk of dementia in the community: the Hisayama studyNeurology201177121126113421931106
  • ChengDNobleJTangMXSchupfNMayeuxRLuchsingerJAType 2 diabetes and late-onset Alzheimer’s diseaseDement Geriatr Cogn Disord201131642443021757907
  • LiJWangYJZhangMVascular risk factors promote conversion from mild cognitive impairment to Alzheimer diseaseNeurology201176171485149121490316